SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of…
Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past…
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ETBRISBANE, Calif.,…
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1)…
Phase 3 study failed to meet one of the success criteria of the primary objectiveRSV program to be discontinuedCOPENHAGEN, Denmark,…
MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem…
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in…
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder valueBOULDER, Colo., July 21, 2023 (GLOBE NEWSWIRE)…
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in…